- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02332135
The Efficacy and Safety of Microwave Ablation for Mild-to-moderate Secondary Hyperparathyroidism Patients Undergoing Hemodialysis
May 22, 2016 updated by: Wenhu Liu
Microwave ablation, as a new method to therapy secondary hyperparathyroidism(SHPT), now is developing rapidly.
However, it is still unknown whether it is effective to accept microwave ablation for hemodialysis patients with mild-to-moderate SHPT.
In this prospective, randomised control and paried clinical trial study, the investigators will observe the efficiency and safety of microwave ablation in hemodialysis patients with mild-to-moderate secondary hyperparathyroidism.
The patients in age-matched control group will accept active Vitamin D therapy.
Study Overview
Status
Unknown
Intervention / Treatment
Detailed Description
Secondary hyperparathyroidism(SHPT) is common in hemodialysis(HD) patients.
SHPT can damage cardiovascular system , bone system, and so forth.
The treatment of SHPT of HD patients includes dietary phosphate restriction, the use of medicines, parathyroidectomy, and microwave ablation, which is a new method booming over the past decade.
However, In the mainland of China, medical therapy is not always successful in achieving adequate control of SHPT.
Oral medications have limitations as well as side effects.
The patients may suffer from the injury of operation, hypoparathyroidism, or recurrence of hyperparathyroidism after parathyroidectomy.
Moreover, the fear of operation for patients also limits its development.
Thus, microwave ablation may become a valuable alternative treatment to help control SHPT in selected patients presenting with enlarged parathyroid gland(s) visible at ultrasonography.
Nevertheless, nowadays there isn't a guideline for doctors to choose when to use microwave ablation to therapy SHPT.
Furthermore, different experts have different views.
Experts in Japan consider that, for SHPT , the earlier one takes microwave ablation, the better he may be, while others think, Just as parathyroidectomy, microwave ablation is merely used for the patient whose intact parathyroid hormone (iPTH) is more than 800pg/ml, or who has serious symptom.
From their perspective, this is no proof that accepting microwave ablation for SHPT in early stage becomes better.
However, as we all know, as the disease progresses, the therapy becomes increasingly difficult.
Since microwave ablation is minimally invasive, safe,the investigators consider, patients who have parathyroid nodular or diffuse hyperplasia demonstrated on ultrasound imaging or radioisotope scan would get more benefit if they undergo microwave ablation the instant that SHPT is diagnosed.
So, In this prospective, randomised control and paried clinical trial study, the investigators will observe the efficiency and safety of microwave ablation in hemodialysis patients with secondary hyperparathyroidism in early stage.
First, the investigators detect the iPTH levels of all the patients in the investigators' blood purification center.
The patients whose iPTH are between 300pg/ml and 800pg/ml and who have parathyroid nodular or diffuse hyperplasia demonstrated on ultrasound imaging or radioisotope scan are chosen to involve in this study.
The patients with age-matched and iPTH between 300pg/ml and 800pg/ml were enrolled in this study.
In the control group, patients will accept vitamin D to treat SHPT, according to the suggestions in K/DOQI guidelines.
Meanwhile, in the microwave ablation group, patients will accept microwave ablation.
Then, all of the patients will be followed for 24 months to compare the rate of achieving the target on iPTH level according to K/DOQI guidelines, the change of iPTH level after MWA,the rate of subjects developed into severe SHPT, as well as calcium and phosphorus level, Quality of Life and mortality in each group.
Study Type
Interventional
Enrollment (Anticipated)
30
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Zongli Diao, master
- Phone Number: +86-01-63138579
- Email: diaoted@163.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100050
- Recruiting
- Beijing Friedship Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- patients with age between 18-75 years.
- patients with parathyroid nodular or diffuse hyperplasia demonstrated on ultrasound imaging or radioisotope scan.
- patients in hemodialysis, whose iPTH is between 300pg/ml and 800pg/ml.
Exclusion Criteria:
- primary or tertiary hyperparathyroidism(hyperparathyroidism after kidney transplantation).
- patient who underwent total parathyroidectomy.
- Known history of parathyroid or other neoplasias in the neck region.
- History of neck trauma.
- major surgery of neck in the last 3 months or in next 4months.
- pregnant or lactating woman.
- patients with severe liver disease and abnormal blood clotting mechanism.
- patients with chronic wasting disease.
- patients who is taking glucocorticoids.
- patients who have other disorders affecting calcium and phosphorus metabolism.
- patients whose concurrent illnesses,disability,or geographical residence would hamper attendance at required study visit.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: microwave ablation group
patients in ultrasonic ablation will be treated by ultrasound guided percutaneous parathyroid gland microwave ablation
|
First, the investigators detect the iPTH levels of all the patients in the investigators' blood purification center.
The patients whose iPTH are between 300pg/ml and 800pg/ml and who have parathyroid nodular or diffuse hyperplasia demonstrated on ultrasound imaging or radioisotope scan are chosen to involve in this study.
Patients are divided into 2 groups at random, the control group and the microwave ablation group.
In the microwave ablation group, patients will accept microwave ablation.
Oral medicines, if needed, will be taken according to the the suggestions in K/DOQI guideline.
|
Active Comparator: control group
patients in control group will be treated by active vitamin D and other general treatments according to the suggestions in K/DOQI guidelines
|
The control group will be treated by active vitamin D and other general treatment,such as dietary phosphate restriction and phosphate binders,according to the suggestions in K/DOQI guideline.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall rate of achieving target for iPTH during the study period.
Time Frame: 12 months
|
The blood level of intact iPTH will be detected every other month for stable patients.
|
12 months
|
The change of iPTH level after MWA.
Time Frame: 12 months
|
The blood level of intact iPTH will be detected every other month for stable
|
12 months
|
The rate of subjects developed into severe SHPT
Time Frame: 12 months
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Calcitriol weekly dosage.
Time Frame: 12 months
|
calcification score in every 6 months
|
12 months
|
Overall rate of achieving target for serum calcium and phosphorus.
Time Frame: 12 months
|
12 months
|
|
Changes of serum calcium and phosphorus after MWA.
Time Frame: 12 months
|
The blood level of bone specific alkaline phosphatase will be detected every other months
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Zongli Diao, master, Beijing Friendship Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2015
Primary Completion (Anticipated)
March 1, 2017
Study Completion (Anticipated)
March 1, 2018
Study Registration Dates
First Submitted
January 4, 2015
First Submitted That Met QC Criteria
January 4, 2015
First Posted (Estimate)
January 6, 2015
Study Record Updates
Last Update Posted (Estimate)
May 24, 2016
Last Update Submitted That Met QC Criteria
May 22, 2016
Last Verified
May 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BJFH-EC/2014-101
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Secondary Hyperparathyroidism
-
The Second Hospital of Nanjing Medical UniversityRecruitingSecondary Hyperparathyroidism;ParathyroidectomyChina
-
Phramongkutklao College of Medicine and HospitalCompletedAlfacalcidol, Secondary Hyperparathyroidism, Hemodialysis
-
Chang Gung Memorial HospitalCompletedSecondary Hyperparathyroidism Due to Renal CausesTaiwan
-
Fundación SenefroAbbVie; Effice Servicios Para la Investigacion S.L.CompletedSecondary Hyperparathyroidism Due to Renal CausesSpain
-
Min-Sheng General HospitalTaipei Medical University; Taipei Medical University Shuang Ho Hospital; National... and other collaboratorsCompletedHyperparathyroidism; Secondary, RenalTaiwan
-
Shanghai Zhongshan HospitalUnknownHyperparathyroidism; Secondary, Renal
-
Shanghai Hengrui Pharmaceutical Co., Ltd.Active, not recruiting
-
Sanwa Kagaku Kenkyusho Co., Ltd.Completed
-
Sanwa Kagaku Kenkyusho Co., Ltd.CompletedSecondary HyperparathyroidismJapan
-
Deltanoid PharmaceuticalsCompletedSecondary HyperparathyroidismUnited States
Clinical Trials on microwave ablation
-
Wenjun WuFirst Affiliated Hospital of Wenzhou Medical UniversityUnknown
-
Assiut UniversityNot yet recruitingThyroid Nodule (Benign)
-
Qianfoshan HospitalShandong Provincial HospitalNot yet recruitingAdvanced Non Small Cell Lung CancerChina
-
Zagazig UniversityCompletedHepatocellular Carcinoma
-
The First Affiliated Hospital with Nanjing Medical...Recruiting
-
Karolinska InstitutetRecruitingPortal Hypertension | Splenomegaly; Congestive, Chronic | Panhematopenia; SplenicSweden
-
The First People's Hospital of ChangzhouCompletedColorectal Cancer
-
University Medical Center GroningenNot yet recruitingBreast Cancer Stage I
-
Shandong Provincial HospitalUnknown